Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-704-4660
Debt
Current Ratio64.69
Quick Ratio64.69
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book22.42
Profitability
Net Income$-20,570,000.00
Net MarginsN/A
Return on Assets-15.14%
Miscellaneous
Employees14
OptionableOptionable
Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions
What is Viking Therapeutics' stock symbol?
Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."
How were Viking Therapeutics' earnings last quarter?
Viking Therapeutics Inc (NASDAQ:VKTX) posted its quarterly earnings data on Friday, November, 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.01. View Viking Therapeutics' Earnings History.
When is Viking Therapeutics' next earnings date?
What price target have analysts set for VKTX?
8 Wall Street analysts have issued 1 year price targets for Viking Therapeutics' stock. Their forecasts range from $15.00 to $43.00. On average, they anticipate Viking Therapeutics' share price to reach $26.2857 in the next twelve months. This suggests a possible upside of 208.5% from the stock's current price. View Analyst Price Targets for Viking Therapeutics.
What is the consensus analysts' recommendation for Viking Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viking Therapeutics.
What are Wall Street analysts saying about Viking Therapeutics stock?
Here are some recent quotes from research analysts about Viking Therapeutics stock:
- 1. Maxim Group analysts commented, "Viking reported 3Q18 with a net loss of ($6.6M) and ended the period with $304M in cash. We have increased expenses going forward as the NASH program moves into later-stage development and additional programs like 0214 move into the clinic." (11/8/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $31 price target. Our peak sales estimates for VK2806 and VK5211 are based on our U.S. projections, and believe overall that peak sales could be conservative because of the size of the addressable markets, the continuing unmet medical need, and no projections for ex-U.S. sales currently. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (11/8/2018)
Has Viking Therapeutics been receiving favorable news coverage?
News stories about VKTX stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Viking Therapeutics earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days.
Are investors shorting Viking Therapeutics?
Viking Therapeutics saw a increase in short interest in December. As of December 31st, there was short interest totalling 23,804,182 shares, an increase of 4.5% from the December 14th total of 22,781,674 shares. Based on an average daily volume of 3,299,958 shares, the days-to-cover ratio is currently 7.2 days. Approximately 37.5% of the company's stock are sold short. View Viking Therapeutics' Current Options Chain.
Who are some of Viking Therapeutics' key competitors?
Some companies that are related to Viking Therapeutics include Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Xencor (XNCR), Endo International (ENDP), Mirati Therapeutics (MRTX), Opko Health (OPK), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), Endocyte (ECYT), Allakos (ALLK), Innoviva (INVA), Ironwood Pharmaceuticals (IRWD) and Zogenix (ZGNX).
Who are Viking Therapeutics' key executives?
Viking Therapeutics' management team includes the folowing people:
- Dr. Brian Lian, Pres, CEO & Director (Age 53)
- Mr. Michael Morneau, VP of Fin. & Admin. (Age 54)
- Ms. Amy Broidrick, Sr. VP of Corp. Devel.
- Dr. Hiroko Masamune, Chief Devel. Officer (Age 62)
- Ms. Marianne Mancini, Sr. VP of Clinical Operations
When did Viking Therapeutics IPO?
(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.
Who are Viking Therapeutics' major shareholders?
Viking Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Fox Run Management L.L.C. (0.02%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Ligand Pharmaceuticals Inc and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics.
Which institutional investors are buying Viking Therapeutics stock?
VKTX stock was acquired by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton and Lawson Macartney. View Insider Buying and Selling for Viking Therapeutics.
How do I buy shares of Viking Therapeutics?
Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viking Therapeutics' stock price today?
One share of VKTX stock can currently be purchased for approximately $8.52.
How big of a company is Viking Therapeutics?
Viking Therapeutics has a market capitalization of $594.55 million. The biotechnology company earns $-20,570,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Viking Therapeutics employs 14 workers across the globe.
What is Viking Therapeutics' official website?
How can I contact Viking Therapeutics?
Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]
MarketBeat Community Rating for Viking Therapeutics (NASDAQ VKTX)
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
